<DOC>
	<DOCNO>NCT00036946</DOCNO>
	<brief_summary>RATIONALE : VEGF Trap may stop growth solid tumor non-Hodgkin 's lymphoma stopping blood flow cancer . PURPOSE : Phase I trial study effectiveness VEGF Trap patient relapse refractory solid tumor non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>VEGF Trap Treating Patients With Relapsed Refractory Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability VEGF Trap patient incurable relapsed refractory solid tumor non-Hodgkin 's lymphoma . - Determine maximum tolerate dose drug patient . - Determine pharmacokinetics drug patient . - Evaluate ability drug bind inactivate circulate vascular endothelial growth factor ( VEGF ) patient . - Determine dose regimen optimal neutralization circulate VEGF patient . - Determine whether antibody drug develop patient . - Assess , preliminarily , ability drug alter tumor vascular permeability tumor growth patient . OUTLINE : This dose-escalation study . Patients receive VEGF Trap subcutaneously daily day 1 , 29 , 36 , 43 , 50 , 57 , 64 absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos VEGF Trap maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 5 additional patient treat MTD . Patients follow 1 4 week . PROJECTED ACCRUAL : A maximum 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm incurable primary metastatic solid tumor nonHodgkin 's lymphoma Relapsed refractory ( e.g. , unresectable ) least 2 standard chemotherapy regimen rituximab No standard curative surgery , chemotherapy , immunotherapy , antitumor therapy , radiotherapy option exist No know suspect squamous cell carcinoma lung No prior concurrent CNS ( brain leptomeningeal ) metastases No prior concurrent primary intracranial tumor MRI CT scan PATIENT CHARACTERISTICS : Age : 25 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL No severe uncontrolled hematologic condition Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2 time ULN Alkaline phosphatase great 2 time ULN PT , PTT , INR normal Renal : Creatinine great ULN No 1+ great proteinuria No severe uncontrolled renal condition Cardiovascular : Electrocardiogram normal LVEF normal echocardiogram MUGA scan within past 12 month since completion prior anthracycline No severe uncontrolled cardiovascular condition No New York Heart Association class III IV heart disease No active coronary artery disease , angina , congestive heart failure , arrhythmia No myocardial infarction within past 6 month No prior concurrent peripheral vascular disease , include : Angiographically ultrasonographically document arterial venous occlusive event Symptomatic claudication No untreated uncontrolled hypertension No treat blood pressure 160/100 mm Hg least 3 repeated determination separate day within past 6 week No symptomatic orthostatic hypotension Pulmonary : No severe uncontrolled pulmonary condition No pulmonary embolism Other : No prior hypersensitivity reaction recombinant protein ( e.g. , VEGF Trap ) No severe uncontrolled gastrointestinal , immunological , musculoskeletal condition No severe uncontrolled psychiatric adverse social circumstance would preclude study No active infection require antibiotic HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception least 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 3 week since prior immunotherapy No concurrent epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy Endocrine therapy : No concurrent adrenal corticosteroid , except low dos replacement therapy patient previously receive suppressive dos adrenal insufficiency No concurrent systemic hormonal contraceptive agent Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy Surgery : See Disease Characteristics At least 3 week since prior surgery ( except fine needle biopsy/aspiration removal/biopsy skin lesion ) No prior surgical procedure correction prophylaxis peripheral vascular insufficiency cerebral ischemic event Other : Recovered prior therapy At least 6 month since prior treatment acute congestive heart failure At least 30 day since prior investigational drug No concurrent standard investigational anticancer agents No concurrent herbal supplement ( `` nutraceuticals '' ) No concurrent anticoagulant antiplatelet drug , ( e.g. , warfarin , heparin , aspirin , nonsteroidal antiinflammatory drug ) except selective cyclooxygenase2 ( COX2 ) inhibitor analgesia No concurrent COX2 inhibitor tumor treatment prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>